リコンビナントタンパク質＿精製したリコンビナントタンパク質 » リコンビナントサイトカイン-免疫活性タンパク質 » IL-17F, Human

IL-17F, Human

Human IL-17F is synthesized as a 153 aa precursor with a 20 aa signal sequence and a 133 aa mature region. Like IL-17A, IL-17F contains one potential site for N-linked glycosylation. IL-17A and IL-17F share 50% aa sequence identity. IL17-F homodimer is produced by an activated subset of CD4+ T cells, termed Th17. IL17-F has been shown to stimulate proliferation and activation of T-cells and PBMCs. IL-17F also regulates cartilage matrix turnover and inhibits angiogenesis.
Z02713
¥34,438.00

Ask us a question
Product Introduction
Species Human
Protein Construction

Expressed with an N-terminal Met.

IL-17F (Arg31-Gln163)
Accession # Q96PD4
Purity > 95% as analyzed by SDS-PAGE
> 95% as analyzed by HPLC
Endotoxin Level < 1 EU/μg of protein by LAL method
Biological Activity Fully biologically active when compared to standard. The ED50 as determined by inducing IL-6 secretion of murine NIH/3T3 cells is less than 20.0 ng/ml, corresponding to a specific activity of > 5.0 × 104 IU/mg.
Expression System E. coli
Theoretical Molecular Weight 30.1 kDa
Formulation Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.2, with trehalose.
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in 4 mM HCl up to 100 μg/ml.
Storage & Stability Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles.

Background
Target Background Human IL-17F is synthesized as a 153 aa precursor with a 20 aa signal sequence and a 133 aa mature region. Like IL-17A, IL-17F contains one potential site for N-linked glycosylation. IL-17A and IL-17F share 50% aa sequence identity. IL17-F homodimer is produced by an activated subset of CD4+ T cells, termed Th17. IL17-F has been shown to stimulate proliferation and activation of T-cells and PBMCs. IL-17F also regulates cartilage matrix turnover and inhibits angiogenesis.
Synonyms Interleukin-17F; IL17F

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.